Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
PTHS
PTHS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PTHS News
Pelthos Therapeutics to Report Q4 and Full Year 2025 Financial Results
1d ago
Newsfilter
Wall Street Analysts Adjust Ratings
Feb 27 2026
Benzinga
Horizon Technology Finance Provides $50 Million Loan Facility to Pelthos Therapeutics
Jan 15 2026
Newsfilter
Pelthos Therapeutics Secures $30 Million Financing to Accelerate ZELSUVMI Commercialization
Jan 13 2026
Globenewswire
Pelthos Appoints Andrew J. Einhorn to Board, Enhancing Financial Management
Dec 23 2025
Globenewswire
Pelthos Launches ZELSUVMI, First FDA-Approved At-Home Treatment for Molluscum Contagiosum
Dec 04 2025
Globenewswire
Linde Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Wednesday
Dec 03 2025
Benzinga
Pelthos Therapeutics Purchases Xepi® (ozenoxacin) Cream, 1%, and Reveals $18 Million Private Convertible Notes Funding
Nov 07 2025
Newsfilter
EXCLUSIVE: Pelthos Acquires Antimicrobial Drug Rights and Raises $18 Million for Commercial Launch Support
Nov 07 2025
Benzinga
Pelthos Obtains US Rights for Xepi and Secures $18 Million in Funding
Nov 07 2025
NASDAQ.COM
Pelthos Therapeutics Set to Attend Investor Conferences This September
Sep 08 2025
Newsfilter
Show More News
